PEELHUNT MARKETING COMMUNICATION

Add

26 September 2019

DATA

Price (close 24/9)	132.6p
Target price	145p
Market cap	£1,610m
Index	FTSE 250
Sector	Real Estate

STATS (POST CHANGES)

Source: Company accounts, Peel Hunt estimates

Y/E Dec	2018A	2019E	2020E	2021E
NetOpInc (£m)	76.4	113.3	128.5	137.8
Adj EPS (p)	5.4	5.8	5.9	6.4
EPSgrowth (%)	2.5	8.8	0.8	9.2
PER (x)	25	23	23	21
DPS (p)	5.4	5.6	5.8	6.0
Div yield (%)	4.1	4.2	4.4	4.5
Adj NAV (p)	105	108	111	115
NAV/3net (p)	102	106	109	113
Disc/Nav (%)	26	23	19	15
Disc/3net (%)	29	25	22	17

CHANGES TO FORECASTS

Source: Company accounts, Peel Hunt estimates

Y/E Dec	2019E Old	2019E New
Adj NAV (p)	107	108
Adj EPS (p)	6.0	5.8
DPS (p)	5.6	n/c

PERFORMANCE

Source: Bloomberg



ANALYSTS

James Carswell +44 (0) 20 7418 8903 james.carswell@peelhunt.com

Sebastian Isola +44 20 3597 8683 sebastian.isola@peelhunt.com

Matthew Saperia +44 (0) 20 3597 8631 matthew.saperia@peelhunt.com

Keith Crawford +44 (0) 20 7418 8973 keith.crawford@peelhunt.com

SPECIALIST SALES

Mark Williamson +44 (0) 20 7418 8857 mark.williamson@peelhunt.com

#Corporate client of Peel Hunt

Primary Health Properties#

PHP

£100m placing for further growth

PHP has raised £100m through the placing of 78.125m shares with new and existing institutional shareholders. Proceeds from the issue will fund an accretive pipeline of development opportunities, the majority of which are in Ireland where income yields are materially higher than in the UK. The issue further increases the company's market value, should enhance liquidity, and reduces LTV. The 128p placing price reflects a 22% premium to NAV and leads to a small NAV upgrade, whilst initial EPS dilution is minimal.

£100m placing of new shares

- On Tuesday, PHP raised £100m of new equity. Following strong demand, the issue size was increased from £75m, with 78.125m shares placed with existing and new institutional shareholders.
- The price of 128p reflects:
 - An 8% discount to the prior day's close (139.8p), a 5% discount to the three-month average price (134.9p) and a 4% discount to the intra-day price when pricing was decided.
 - A 22% premium to the adjusted EPRA NAV per share as of June 2019 (105.2p).
 - A dividend yield of 4.4%, which is fully covered by recurring earnings.

Use of proceeds

The proceeds of the issue will be used to fund an increasing number of development opportunities both in Ireland and the UK.

- PHP is contracted to fund the development of eight new centres for £60m.
 The majority (£45m) are located in Ireland, where yields are materially higher than the UK.
- The company has another £70m of near-term development opportunities in legal due diligence and/or with commercial terms agreed. The majority of these are also located in Ireland (£50m).
- In addition to the above, the company has various asset management projects that will utilise c£5m, and the company retains its significant acquisition pipeline of standing investments.

Initial financial implications

- We estimate that the placing initially reduces LTV to 44% (from 48%). We then expect LTV to gradually rise as acquisitions/developments are committed. We estimate that LTV rises by around 2% for every £100m that is deployed.
- The c78m new shares equates to around 6% of issued share capital and simply assuming that the proceeds initially sit on the balance sheet as cash, the initial dilution for FY19 is likely to be around 2% given the shares will be in issue for a quarter of the financial year.

- As acquisitions/developments complete, this will clearly be accretive to EPS given the low marginal cost of debt, the low running costs of the business and the significantly higher yields on offer in Ireland.
- The placing price is at a 22% premium to June 2019 NAV and even after issue costs, the raise will be accretive to our December 2019 NAV forecast, adding approximately 1% or 1p.







Benefits of the raise

- Accretion As shown in charts 1 and 2, even assuming relatively low leverage against the fresh equity (40% LTV), expansion in both the UK and Ireland will both be accretive to shareholders given the low marginal cost of debt and the low ongoing management charges. The issue price of 128p will also be accretive to the NAV, which was last reported at 105p.
- Additional liquidity The issue will further increase PHP's market cap to above £1.6bn. This is almost double the market cap of just 12 months ago and is more than four times the market cap of five years ago.
- Reduces LTV The company's LTV reduces by around 400bps to 44% immediately after the issue and, on our forecasts, LTV remains lower by 300bps on average over each of the next three financial years.
- Expansion in Ireland The majority of PHP's near-term pipeline is located in Ireland where yields that are almost 100bps higher than the UK offer additional income and also look set to benefit from greater yield compression. We estimate that the near-term pipeline will increase PHP's Irish portfolio to c€280m (from €174m at June 2019).

Debt refinancing opportunity remains

- Earlier this month, PHP issued €70m of secured notes, attracting a fixed rate of 1.509% for a period of 12 years.
- With half of the c£1.4bn debt book maturing in the next 5½ years, there is an opportunity to reduce the average cost of debt from 3.75% reported in June.
- Such refinancing activity and the accretion it could deliver is not captured in our forecasts. The company has around £1.4bn of debt facilities and we estimate that for every 25bps in interest saving, EPS will increase by around 5%.





New Peel Hunt forecasts

December 2019 forecasts

- EPRA NAV per share is increased marginally to 108p (from 107p) to account for the issue price, which is at a material premium. We forecast an 8% total return for 2019.
- Adj EPS is reduced slightly to 5.8p (from 6.0p) to account for the initial cashdrag following the equity placing.
- DPS is unchanged at 5.6p for a 4.4% yield (on the issue price), which remains fully covered by earnings.

December 2020 and December 2021 forecasts

- Our December 2020 and December 2021 EPS forecasts are reduced slightly to 5.9p (from 6.2p) and 6.4p (from 6.6p), respectively. This accounts for the marginal EPS dilution following the raise and until the development assets are contracted, built out, and income generating.
- EPRA NAV per share for 2020 and 2021 remain unchanged and we forecast total returns of 8% and 9% over 2020 and 2021.
- DPS of 5.8p and 6.0p for 2020 and 2021, respectively are unchanged for yields of 4.4% and 4.5%.

Table 1: New Peel Hunt forecasts

Source: Company accounts, Peel Hunt estimates


	FY19E		FY20E		FY21	.E
	New	Old	New	Old	New	Old
Adj EPS	5.8	6.0	5.9	6.2	6.4	6.6
DPS	5.6	5.6	5.8	5.8	6.0	6.0
Yield	4.2%		4.4%		4.5%	
Cover	1.0x		1.0x		1.1x	
EPRA NAV per share	108	107	111	111	115	115
Discount/premium	23%		19%		15%	
NAV growth	2.5%		3.1%		3.7%	
Total return	7.9%		8.4%		9.1%	


Key financials and valuation metrics


Table 2: Income statement Source: Company accounts, Peel Hunt estimates								
Y/end Dec	FY14A	FY15A	FY16A	FY17A	FY18A	FY19E	FY20E	FY21E
Gross rent	60.0	63.1	67.4	72.5	79.6	118.8	134.0	143.7
Direct costs	-0.7	-0.9	-0.9	-1.2	-3.2	-5.5	-5.5	-5.9
Development/trading gains (recurring)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net rent	59.3	62.3	66.6	71.3	76.4	113.3	128.5	137.8
Admin expenses	-6.8	-6.8	-7.3	-8.2	-8.6	-10.3	-12.4	-13.0
Fee income	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	52.5	55.5	59.2	63.1	67.8	103.0	116.0	124.8
PH cost ratio	-13%	-12%	-12%	-13%	-15%	-13%	-13%	-13%
Net finance costs	-34.3	-33.7	-32.5	-31.6	-29.7	-40.9	-44.7	-47.3
Contribution from JVs/associates	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Recurring PBT	18.2	21.7	26.7	31.5	38.1	62.1	71.3	77.5
Current tax	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Adjusted earnings	18.2	21.7	26.7	31.5	38.1	62.1	71.3	77.5
Weighted average shares	444m	446m	560m	601m	709m	1,077m	1,214m	1,214m
Adjusted earnings per share	4.1p	4.9p	4.8p	5.2p	5.4p	5.8p	5.9p	6.4p
P/E ratio	32x	27x	28x	25x	25x	23x	23x	21x
Ordinary dividend per share	4.9p	5.0p	5.1p	5.3p	5.4p	5.6p	5.8p	6.0p
Special dividend per share	0.0p	0.0p	0.0p	0.0p	0.0p	0.0p	0.0p	0.0p
Dividend yield (incl. special)	3.7%	3.8%	3.9%	4.0%	4.1%	4.2%	4.4%	4.5%
Dividend cover (excl. special)	0.8x	1.0x	0.9x	1.0x	1.0x	1.0x	1.0x	1.1x


Table 3: Balance sheet Source: Company accounts, Peel Hunt estimates								
Y/end Dec	FY14A	FY15A	FY16A	FY17A	FY18A	FY19E	FY20E	FY21E
Investment property	1,026	1,101	1,220	1,362	1,503	2,390	2,579	2,775
Trading/development assets	0	0	0	0	0	0	0	0
Investment in JVs/associates	0	0	0	0	0	0	0	0
Assets held for sale	0	0	0	0	0	0	0	0
Cash	12	3	5	4	6	150	26	29
Other assets	6	4	3	7	5	15	15	15
TOTAL ASSETS	1,044	1,108	1,229	1,372	1,514	2,555	2,620	2,819
Bank debt and bonds	-667	-698	-668	-730	-676	-1,194	-1,219	-1,369
Other	-68	-65	-61	-55	-50	-78	-78	-78
TOTAL LIABILTIES	-735	-762	-729	-786	-726	-1,272	-1,297	-1,447
LTV	64%	63%	54%	53%	45%	44%	46%	48%
Basic NAV	£309m	£345m	£499m	£587m	£788m	£1,284m	£1,323m	£1,372m
Adj NAV	£422m	£466m	£622m	£687m	£834m	£1,308m	£1,348m	£1,396m
Closing number of shares	530m	531m	683m	683m	793m	1,214m	1,214m	1,214m
Adj NAV per share	80p	88p	91p	101p	105p	108p	111p	115p
Discount/Premium	66%	51%	46%	32%	26%	23%	19%	15%


Key financials and valuation metrics











Key financials and valuation metrics

Chart 10: Historic NAV growth and premium/discount Source: Company accounts, Peel Hunt estimates 35% 14% 30% 12% 25% 10% 20% 8% 6% 4% 10% 5% 2% 0% 0% Aug-14 Aug-15 Aug-16 Aug-19 Aug-17 Aug-18 ■ NAV discount (left axis) - NAV growth (right axis)







Chart 12: Relative share price performance









■ Equivalent yield ■ Net Initial Yield

Recommendation structure and distribution

Recommendation distribution at 25 September 2019

All research published in the last 90 days

	Corporate No	Corporate %	No	%	Corporate %	%
Buy	89	80	195	56	81	57
Add	11	10	52	15	10	15
Hold	8	7	79	23	7	21
Reduce	0	0	11	3	0	3
Sell	0	0	8	2	0	2
Under Review	3	3	5	1	2	1

Peel Hunt's Recommendation Structure is as follows:

Buy, > +15% expected absolute price performance over 12 months

Add, +5-15% range expected absolute price performance over 12 months

Hold, +/-5% range expected absolute price performance over 12 months

Reduce, -5-15% range expected absolute price performance over 12 months

Sell, > -15% expected absolute price performance over 12 months

Under Review (UR), Recommendation, Target Price and/or Forecasts suspended pending market events/regulation

NB The recommendation is the primary driver for analyst views. The target price may vary from the structure due to market conditions, risk profile of the company and capital returns

Research Disclosures

Number	Disclosure
1	Company is a corporate client of Peel Hunt
2	The Analyst has a shareholding in this Company
3	The Company holds > 3% in Peel Hunt
4	Peel Hunt makes a market in this Company
5	Peel Hunt is Broker to this Company and therefore provides investment services to the Company
6	During the last 12 months Peel Hunt has received compensation from this company for the provision of investment banking services
7	During the last 12 months Peel Hunt has acted as a sponsor/broker/ NOMAD/ financial advisor for an offer of securities from this company
8	Peel Hunt holds >5% in Company (calculated under Market Abuse Regulation (EU) 596/2014)
9	1% beneficial ownership (calculated for purposes of FINRA under Section 13(d)/(g) of the Securities Exchange Act of 1934 and IIROC Rule 3400)
10	Peel Hunt holds a net long position that exceeds 0.5% in the Company (calculated under Market Abuse Regulation (EU) 596/2014).
11	Peel Hunt holds a net short position that exceeds 0.5% in the Company (calculated under Market Abuse Regulation (EU) 596/2014).

Recommendation history

Company	Disclosures	Date	Rec	Price	Target Price
Primary Health Properties	1,4,5,7	17 Jun 19	Add	139p	145p
		18 Mar 19	Buy	130p	140p
		15 Mar 19	Buy	129p	UR
		04 Sep 18	Buy	114p	125p

PEEL HUNT Primary Health Properties# 26 September 2019

This research material (the "Report") is produced by Peel Hunt LLP, which is authorised and regulated in the United Kingdom by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange. The Peel Hunt LLP analysts that prepare such are stated on the Report.

The Report must be treated as a marketing communications for the purposes of Directive 2014/65/EU as these have not been prepared in accordance with legal requirements designed to promote the independence of research. Although Peel Hunt LLP is not subject to any prohibition on dealing ahead of the dissemination of investment research, Peel Hunt LLP applies this prohibition through its internal systems and controls. The analyst or analysts responsible for the content of the Report certify that:

- (1) the views expressed and attributed to the research analyst or analysts in the Report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate. Information that is non-factual, interpretive, assumed or based on the analyst's opinion shall not be interpreted as facts and where there is any doubt as to reliability of a particular source, this is indicated; and
- (2) no part of the research analyst's or analysts' compensation will be directly or indirectly related to the specific recommendations or views contained in this research report and, as far as they are aware, there are no relationships or circumstances (including conflicts of interest) that may in any way impair the objectivity of this recommendation, and that where any such relationship, conflict or circumstance exists concerning any financial instrument or issuer to which this recommendation directly or indirectly relates, this has been disclosed. This statement applies equally to any persons closely associated with such analyst.

Peel Hunt LLP has effective organisational and administrative arrangements set up within the firm for the prevention and avoidance of conflicts of interest with respect to research recommendations, including information barriers. For information regarding potential conflicts of interest and the general approach taken by Peel Hunt LLP in relation to conflicts of interest, please contact mar-disclosures@peelhunt.com.

The Report is for the use of the addressees only and is not intended for nor should be disseminated to Retail Customers as defined in Directive 2014/65/EU. It may not be copied or distributed to any other person without the written consent of Peel Hunt LLP and may not be distributed or passed on, directly or indirectly, to any other class of persons, Peel Hunt LLP may in its discretion distribute this document to any other person to whom it could lawfully be distributed by an unauthorised person and without its content being approved by an authorised person.

Each Report has been prepared using sources believed to be reliable, however we do not represent it is accurate or complete. Neither Peel Hunt LLP, nor any of its partners, members, employees or any affiliated company accepts liability for any loss arising from the use of the Report or its contents. It is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. While Peel Hunt LLP endeavours to update on a reasonable basis the information and opinions contained herein, there may be regulatory, compliance or other reasons that prevent us from doing so. The opinions, forecasts, assumptions, estimates, derived valuations and target price(s) contained in this material are as of the date indicated and are subject to change at any time without prior notice.

The Report does not constitute a personal recommendation and the investments referred to may not be suitable for the specific investment objectives, financial situation or individual needs of recipients and should not be relied upon in substitution for the exercise of independent judgement. Past performance is not necessarily a guide to future performance and an investor may not get back the amount originally invested. The stated price of any securities mentioned herein is not a representation that any transaction can be effected at this price.

The date and time when the production of the Reports is completed is the date and time stated on the relevant Report. Additionally, unless specifically stated otherwise, the date and time for prices quoted for all stocks mentioned in the relevant Report is the same as that shown on the front page of the relevant Report. For further detail of when any relevant Report was first published, please contact mar-disclosures@peelhunt.com.

For further detail of our forecasts on any stock/company, please contact mar-disclosures@peelhunt.com. Peel Hunt LLP's methodology for assigning recommendations includes (unless otherwise indicated) the following: market capitalisation, maturity, growth/value, volatility and expected total return. Target prices are derived from variety of valuation methodologies, which include (unless otherwise indicated), but are not restricted to, analysis of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE). All investment recommendations provided are subject to changes in macro-economic information, such as GDP, unemployment and inflation. Micro-economic information about the issuer such as quantitative and qualitative factors may also be taken into account.

Peel Hunt LLP Moor House 120 London Wall London EC2Y 5ET T: +44 (0) 20 7418 8900 F: +44 (0) 20 7305 7088 The time horizon for both recommendations and target prices is 12 months, unless otherwise stated in the relevant Report. For details of valuation methodologies, please see the relevant pages of each Report or previous Report.

The frequency of updates to Reports is not planned. Analysts endeavour to remain up-to-date on stocks at all times, and generally write regular (but not frequent) Reports. Analysts will usually write in the event of a significant development. It should be assumed that any Report has been reviewed by the issuer/company for factual accuracy, and that changes will have been incorporated as a result of that review.

It should be assumed that for the purposes of Peel Hunt LLP's business, including Market Making, Peel Hunt LLP may hold 0.5%, or more, of the stocks it provides Reports in relation to. Financial instruments referred to in Reports where Peel Hunt LLP is not a market maker, it may be a liquidity provider and engage in transactions in a manner inconsistent with the recommendations in its Reports.

A list of recommendations made in the past 12 months by Peel Hunt LLP can be requested by contacting mar-disclosures@peelhunt.com.

Peel Hunt LLP, its partners, members, employees or any affiliated company may have a position or holding in any of the securities it researches, or in a related instrument. The Reports are approved for communication by Peel Hunt LLP in the UK and to EEA market professionals who have registered with Peel Hunt LLP to receive such information.

Unless otherwise stated, Peel Hunt LLP owns the intellectual property rights and any other rights in all material shown on the Portal. No part of any Report may be modified, photocopied or duplicated in any form by any means or redistributed, transmitted, published or derivative works created without the prior consent of Peel Hunt LLP. By accepting access to the Portal you agree that you have read the above disclosure and to be bound by the foregoing limitations / restrictions.

Not for onward distribution into the People's Republic of China.

US Disclosure: Peel Hunt LLP Reports are distributed to US investors by Peel Hunt Inc., which is a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC"). Peel Hunt LLP accepts responsibility for the contents of this Report and it has not been altered in any way by Peel Hunt Inc. Peel Hunt LLP and/or its affiliates may hold 1% or more of any class of common equity securities in the issuer that the Reports cover. Disclosures in relation to Peel Hunt LLP and/or any affiliate's role in: (1) managing or co-managing a public offering of securities for the issuer; (2) receiving compensation for investment banking services from the issuer in the past 12 months; (3) expecting or intending to receive compensation for investment banking services from the issuer in the next three months; and, (4) making a market in the issuers securities; are set out in the main disclosure section of this publication. Canada Disclosure: Peel Hunt LLP Reports may only be distributed by Peel Hunt LLP to Permitted Clients as defined in Section 1.1 of the National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations ("NI 31-103") in reliance on the International Dealer Exemption and International Adviser Exemption pursuant to subsections 8.18(2) and 8.26(3) and Notification to Clients of the prescribed information under subsections 8.18(4)(b) and 8.26(4)(e) of NI 31-103 in Alberta, British Columbia, Ontario and Quebec. Peel Hunt LLP is not registered in the local jurisdiction to provide advice on securities or to trade in securities. Peel Hunt LLP is: (1) registered in England and Wales with its principal place of business in the United Kingdom; (2) a member of the London Stock Exchange; and (3) regulated by the FCA. All or substantially all of the Company's assets may be situated outside of Canada. There may be difficulty enforcing legal rights against the Company because of the above. The Reports have not been prepared in accordance with the disclosure requirements of Dealer Member Rule 3400 - Research Restrictions and Disclosure Requirements of the Investment Industry Regulatory Organisation of Canada ("IIROC").

Republic of South Africa Disclosure: Peel Hunt LLP Reports may only be distributed to clients as defined in the FAIS Notice 37 of 2014 issued by the Financial Services Board. These Reports are distributed by Peel Hunt LLP under the exemption granted from section 7(1) of the Financial Advisory and Intermediary Services Act, 2002.

Australia Disclosure: Peel Hunt LLP Reports are distributed in Australia by Peel Hunt LLP under the exemption in Australian Securities and Investments Commission ("ASIC") Class Order [CO 03/1099] from the requirement to hold an Australia Financial Services Licence. This research may only be distributed to a "Sophisticated Investor" or a "Professional Investor" and a "Wholesale Client" (within the meaning of sections 708(10), 708(11) and 761G of the Corporations Act 2001 (Cth) (the "Act"), respectively), being a person to whom an offer of securities can be made without disclosure under Chapter 6D of the Act.

Peel Hunt LLP Moor House 120 London Wall London EC2Y 5ET T: +44 (0) 20 7418 8900 F: +44 (0) 20 7305 7088